Released on = April 4, 2006, 8:11 am

Press Release Author = Kevin Nally

Industry =

Press Release Summary = Interview Available on Zangani Website and Via Podcast

Press Release Body = Flemington, N.J., April 4th, 2006 Zangani Investor Community,
an outsourced IR and Business Development firm announced today that they interviewed
Michael Weiner, President and CEO of Biophan Technologies, Inc., on April 3rd, 2006.
Mr. Riedlinger discussed the latest business opportunities for the company including
its recent announcement that it intends to enter into negotiations for a strategic
collaboration with Siemens Medical Solutions MRI Division in Europe.

To access the interview, please visit the Zangani Investor Community at:
www.zangani.com/biophan/2006-0403-biph. The interview is also available via Podcast
at www.zangani.com or through the itunes music store.

About Biophan Technologies, Inc.

Biophan develops and markets cutting-edge technologies for the medical device
industry that provide competitive advantages. The Company\'s founding goal was to
make all biomedical devices capable of safely and successfully working with magnetic
resonance imaging (MRI), problems which the Company has solved and begun to license
to leading device manufacturers. The Company\'s mission has expanded to provide other
technologies which will improve the delivery of healthcare. Biophan\'s technologies
enable medical systems such as pacemakers, interventional surgical devices such as
catheters and guidewires, and implants such as stents to be safely and/or
effectively imaged under MRI. The Company is helping to commercialize the
MYO-VAD(TM), a novel, MRI-compatible ventricular assist device which has significant
potential to improve the treatment of many forms of acute and chronic heart disease.
Other applications in development include drug delivery and power systems which
derive energy from body heat. Committed to growth through innovation and
developmental leadership, Biophan and its licensors now hold a total of 156 U.S.
patents, licenses, or applications, plus international applications. This total
includes 50 issued U.S. patents, 8 recently-allowed applications that will issue as
patents in the near future, and 98 pending applications at various stages of
examination at the U.S. Patent and Trademark Office. The patents cover areas
including nanotechnology (nanomagnetic particle coatings), medical device designs,
radio frequency filters, polymer composites, thermoelectric materials, and
photonics. Biophan has joint development and licensing agreements with Boston
Scientific Corporation and NASA\'s Ames Center for Nanotechnology. Biophan is traded
on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock
Exchange under the symbol BTN.

About Zangani

Zangani is an outsourced IR and Business Development firm specializing in small cap
and micro cap companies. They provide clients with an array of investor relations
products, including customized company strategies, community forums, and webcasting
which are tailored for small cap budgets. For more information please visit their
website at http://www.zangani.com

Note: Except for the historical information contained herein, this press release
contains, among other things, certain forward-looking statements, within the meaning
of the Private Securities Litigation Reform Act of 1995, that involve risks and
uncertainties. Such statement may include, without limitation, statements with
respect to the Company's plans, objectives, expectations and intentions and other
statements identified by words such as "may", "could", "would", "should",
"believes", "expects", "anticipates", "estimates", "intends", "plans" or similar
expressions. These statements are based upon the current beliefs and expectations
of the Company's management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in the forward-looking
statements. These forward-looking statements involve certain risks and
uncertainties that are subject to change based on various factors (many of which are
beyond the Company's control).

L.G. Zangani, LLC provides financial public relations service to the Company. As
such L.G. Zangani, LLC and/or its officers, agents and employees, receives
remuneration for public relations and or other services in the form of monies,
capital stock in the Company, warrants or options to purchase capital in the
Company. The full disclaimer can be read here at http://www.zangani.com/disclaimer.

Contact:
Kevin Nally
Zangani Investor Community
9 Main Street
Flemington, NJ 08822
office@zangani.com
http://www.zangani.com


Web Site = http://w

Contact Details = Zangani Investor Community
Kevin Nally
9 Main Street
Flemington, NJ 08822
908-788-9660 x 625
office@zangani.com
http://www.zangani.com